PARP抑制剂在肿瘤治疗中的药代动力学与药效学
本综述概述了奥拉帕利、尼拉帕利、芦卡帕利和他拉唑帕利四种PARP抑制剂的药代动力学特性,包括肝肾功能不全、食物影响和药物相互作用,并总结了暴露-疗效和暴露-毒性关系。四种药物血浆暴露个体间变异中至高,高暴露与毒性增加相关,他拉唑帕利有暴露-疗效关系描述,其他三种尚不明确。
要点
- 奥拉帕利和芦卡帕利每日两次给药,经CYP酶广泛代谢,药物相互作用风险高。
- 尼拉帕利和他拉唑帕利每日一次给药,药物相互作用风险较低。
- 四种PARP抑制剂暴露个体间变异中至高,高暴露与血液学毒性增加相关。
核心结论
- 四种PARP抑制剂血浆暴露个体间变异中至高,高暴露与毒性增加相关,他拉唑帕利有暴露-疗效关系描述,其他三种尚不明确。
研究设计与样本
- 综述,总结奥拉帕利、尼拉帕利、芦卡帕利和他拉唑帕利的药代动力学特性及药效学关系。
主要发现
- 奥拉帕利和芦卡帕利每日两次口服,经细胞色素P450酶广泛代谢,是多种酶和药物转运体的抑制剂,药物相互作用风险高。
- 尼拉帕利和他拉唑帕利每日一次口服,尼拉帕利药物相互作用风险较低,他拉唑帕利风险极小。
- 四种PARP抑制剂血浆暴露个体间变异中至高,较高暴露与毒性增加相关,主要为血液学毒性。
- 他拉唑帕利有暴露-疗效关系描述,奥拉帕利、尼拉帕利和芦卡帕利的暴露-疗效关系尚不明确。
关键数值与推荐
- 四种PARP抑制剂半数抑制浓度均在纳摩尔范围,作用相似。
- 他拉唑帕利有暴露-疗效关系描述,奥拉帕利、尼拉帕利和芦卡帕利尚不明确。
临床怎么用
- 临床需关注奥拉帕利和芦卡帕利的药物相互作用风险,尼拉帕利和他拉唑帕利风险较低。
- 高暴露与血液学毒性增加相关,提示需关注暴露水平与毒性监测。
- 治疗药物监测可能有助于改善PARP抑制剂的给药。
局限性
- 奥拉帕利、尼拉帕利和芦卡帕利的暴露-疗效关系尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer. Poly (ADP-ribose) polymerase inhibitors are potent inhibitors of the PARP enzymes with comparable half-maximal inhibitory concentrations in the nanomolar range. Olaparib and rucaparib are orally dosed twice a day, extensively metabolized by cytochrome P450 enzymes, and inhibitors of several enzymes and drug transporters with a high risk for drug-drug interactions. Niraparib and talazoparib are orally dosed once a day with a lower risk for niraparib and a minimal risk for talazoparib to cause drug-drug interactions. All four PARP inhibitors show moderate-to-high interindividual variability in plasma exposure. Higher exposure is associated with an increase in toxicity, mostly hematological toxicity. For talazoparib, exposure-efficacy relationships have been described, but for olaparib, niraparib, and rucaparib this relationship remains inconclusive. Further studies are required to investigate exposure-response relationships to improve dosing of PARP inhibitors, in which therapeutic drug monitoring could play an important role. In this review, we give an overview of the pharmacokinetic properties of the four PARP inhibitors, including considerations for patients with renal dysfunction or hepatic impairment, the effect of food, and drug-drug interactions. Furthermore, we focus on the pharmacodynamics and summarize the available exposure-efficacy and exposure-toxicity relationships.
引用
- Bruin MAC, Sonke GS, Beijnen JH, et al. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Clin Pharmacokinet. 2022. PMID: 36219340. doi:10.1007/s40262-022-01167-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。